1. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
- Author
-
Vijaya Raj Bhatt, Rodrigo Martino, Martin S. Tallman, Rafael Madero-Marroquin, Siddhartha Ganguly, Michael R. Grunwald, Mahmoud Aljurf, Stefan O. Ciurea, Ankit Kansagra, Taiga Nishihori, Brenda M. Sandmaier, Jacob M. Rowe, Alexandra Gomez-Arteaga, Amer Assal, Jan Cerny, Gerhard C. Hildebrandt, Shahinaz M. Gadalla, Jonathan Sanchez, Shahrukh K. Hashmi, Mei-Jie Zhang, Christopher Bredeson, Hillard M. Lazarus, Leo F. Verdonck, Akshay Sharma, Paul Castillo, Richard F. Olsson, Wael Saber, Fotios V. Michelis, Sachiko Seo, Kamal Menghrajani, Christopher S. Hourigan, Hongtao Liu, Ran Reshef, Michael Byrne, Sunita Nathan, Partow Kebriaei, Hai-Lin Wang, Lohith Gowda, Melhem Solh, Maxwell M. Krem, Zachariah DeFilipp, Yanming Zhang, Sherif M Badawy, Robert Peter Gale, Nosha Farhadfar, Ulrike Bacher, David A. Rizzieri, Nelli Bejanyan, Christopher G. Kanakry, Bipin N. Savani, Mark R. Litzow, Khalid Bo-Subait, Daniel J. Weisdorf, Saurabh Chhabra, Farhad Khimani, and Celalettin Ustun
- Subjects
Oncology ,medicine.medical_specialty ,biology ,business.industry ,Remission Induction ,Hematopoietic Stem Cell Transplantation ,Cytogenetics ,Myeloid leukemia ,Hematology ,Disease ,Leukemia, Myeloid, Acute ,Increased risk ,KMT2A ,Cell transplantation ,Recurrence ,hemic and lymphatic diseases ,Internal medicine ,Overall survival ,medicine ,biology.protein ,Humans ,610 Medicine & health ,Risk classification ,business - Abstract
Little is known about whether risk classification at diagnosis predicts post-hematopoietic cell transplantation (HCT) outcomes in patients with acute myeloid leukemia (AML). We evaluated 8709 patients with AML from the CIBMTR database, and after selection and manual curation of the cytogenetics data, 3779 patients in first complete remission were included in the final analysis: 2384 with intermediate-risk, 969 with adverse-risk, and 426 with KMT2A-rearranged disease. An adjusted multivariable analysis detected an increased risk of relapse for patients with KMT2A-rearranged or adverse-risk AML as compared to those with intermediate-risk disease (hazards ratio [HR], 1.27; P = .01; HR, 1.71; P < .001, respectively). Leukemia-free survival was similar for patients with KMT2A rearrangement or adverse risk (HR, 1.26; P = .002, and HR, 1.47; P < .001), as was overall survival (HR, 1.32; P < .001, and HR, 1.45; P < .001). No differences in outcome were detected when patients were stratified by KMT2A fusion partner. This study is the largest conducted to date on post-HCT outcomes in AML, with manually curated cytogenetics used for risk stratification. Our work demonstrates that risk classification at diagnosis remains predictive of post-HCT outcomes in AML. It also highlights the critical need to develop novel treatment strategies for patients with KMT2A-rearranged and adverse-risk disease.
- Published
- 2022